Видео ютуба по тегу Aml Phase Two Expansion

A Phase II trial evaluating E7820 in patients with AML with splicing factor mutations
A Phase II trial evaluating E7820 in patients with AML with splicing factor mutations
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Update on a Phase I/II study of ziftomenib in patients with R/R AML
Update on a Phase I/II study of ziftomenib in patients with R/R AML
A Phase II trial of venetoclax and cytarabine with or without midostaurin in older patients with AML
A Phase II trial of venetoclax and cytarabine with or without midostaurin in older patients with AML
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
CLAD-LDAC-Ven induction therapy in AML: insights from a Phase II trial
CLAD-LDAC-Ven induction therapy in AML: insights from a Phase II trial
Key Lecture from the 2025 ASCO Annual and the EHA 2025 Congress — Acute Myeloid Leukemia
Key Lecture from the 2025 ASCO Annual and the EHA 2025 Congress — Acute Myeloid Leukemia
A Phase II trial investigating crenolanib plus salvage chemotherapy in R/R FLT3-mutated AML
A Phase II trial investigating crenolanib plus salvage chemotherapy in R/R FLT3-mutated AML
Phase I/II study of novel FLT3 inhibitor HM43239 in R/R AML
Phase I/II study of novel FLT3 inhibitor HM43239 in R/R AML
ArcelorMittal Liberia Phase II Expansion Project
ArcelorMittal Liberia Phase II Expansion Project
Long-term follow-up from a Phase II trial of olutasidenib in IDH1-mutated AML
Long-term follow-up from a Phase II trial of olutasidenib in IDH1-mutated AML
A Phase II trial of busulfan, fludarabine, cladribine, thiotepa, and venetoclax conditioning for AML
A Phase II trial of busulfan, fludarabine, cladribine, thiotepa, and venetoclax conditioning for AML
How quickly does AML progress? #AML
How quickly does AML progress? #AML
Phase II study of vibecotamab in MRD+ AML and MDS & CMML after HMA failure
Phase II study of vibecotamab in MRD+ AML and MDS & CMML after HMA failure
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Dr. Levis on a Phase II Trial Examining Quizartinib in AML
Dr. Levis on a Phase II Trial Examining Quizartinib in AML
Results of Phase II trial of olutasidenib in patients with R/R mIDH1 AML
Results of Phase II trial of olutasidenib in patients with R/R mIDH1 AML
KO-539: a KMT2A inhibitor with promising results in R/R AML
KO-539: a KMT2A inhibitor with promising results in R/R AML
AML phase 2 class presentation for CIS
AML phase 2 class presentation for CIS
Safety run-in of a Phase II trial of CPX-351 plus pomalidomide in AML with MDS-related changes
Safety run-in of a Phase II trial of CPX-351 plus pomalidomide in AML with MDS-related changes